FLT3 is a class‐III receptor tyrosine kinase and activating mutations occur in about 30% of patients with AML, co‐occur particularly with NPM1‐mutations, and internal tandem duplications (ITD) in FLT3 are associated with inferior treatment outcome.114. The gene discussed is NPM1; the disease is acute myeloid leukemia.